الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 82 |  |  |
| | | from | 82 | | |
Abstract
The management of diabetic macular edema (DME) has witnessed multiple developments in the past decades. For several decades, the use of macular photocoagulation alone was the standard of treatment, which was shifted later to multiple intravitreal injection and implants. Nowadays, established patients with DME undergo multiple intravitreal injections, few sessions of laser apart from a strict emphasis on control of systemic parameters.
Two multicentric trials; FIELD (14) and ACCORD (15) studies, assessed the role of fenofibrate in reduction of frequency of first laser treatment for macular edema & progression of diabetic retinopathy over 5 years with significant positive effects. These two trials, however, have not evaluated the effect of fenofibrate on the preexisting macular edema requiring treatment.
The aim of this study was to evaluate the role of addition of oral fenofibrate to the routine management of diabetic macular edema (DME) and quantify its effect on macular thickness and visual acuity in DME. Our study was a prospective randomized controlled trial. The study was done in Ophthalmology Department at Menoufia University Hospitals.
It included 100 eyes of patients with type 2 diabetes complicated with DME. Patients were randomized into two groups: Treatment group (group A) (oral fenofibrate 160 mg/day) and control groups (group B). Patients were randomized by using a computer-generated sequence. Each group was 50 eyes.
Any patient with central macular thickness (CMT) measured on stratus optical coherence tomography (OCT) of equal to or more than 250 μ, HbA1c of < 9, normal creatinine levels and systemic blood pressure <140/90 mmHg was included in our study. Patients with any of the following criteria were excluded from this stu